Revolution Medicines, Inc. (RVMD)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Revolution Medicines topped consensus EPS expectations in the third fiscal quarter of 2026, reported November 4, 2026, with EPS of -$1.90 topping the -$2.35 estimate by $0.45, while net income was a loss of roughly $407.5 million, down 33.5% year over year and versus a loss of about $305.2 million a year ago. Revenue came in at about $197.6 million, supporting gross profit of roughly $197.2 million and a gross margin of ~100%, while operating results remained deeply negative with operating income of around -$373.1 million and an operating margin of roughly -189%. EPS was down 18.0% year over year (from -$1.61 a year ago), tracking the wider net loss for the period as the clinical-stage precision oncology pipeline, including programs such as RMC-4630, RMC-5845, and RMC-5552, continued to drive operating spend ahead of marketed product revenue. For the next period, consensus calls for EPS of -$1.90 on revenue of $184.0 million.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a clinical-stage precision oncology biotechnology company listed on NASDAQ as RVMD. The company develops targeted cancer medicines aimed at pathways central to RAS-driven tumors, and its work centers on a pipeline of inhibitors designed for specific signaling proteins and mutation states rather than marketed products.
Today's Snapshot
The day ended with RVMD 1.8% lower at 159.82, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level. Revolution Medicines won European approval for Rasonque, its pancreatic-cancer drug.
Trading Volume
Below 10d avg (3.3M)
2.2M
vs S&P 500 Today
Underperforming Market
-1.50%
Updated: November 18, 2026 at 21:17 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$157.22 - $188.29Sell
- RSI (14)34.16Neutral
- Stochastic %K (14, 3, 3)2.27Buy
- MACD Level (12, 26)-7.15Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.